Developing Breakthrough Therapies for Rare Inflammatory Diseases

Anabasum is a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Learn more Career Opportunities

Developing Breakthrough Therapies for Rare Inflammatory Diseases

Anabasum is a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Learn more Career Opportunities

Developing Breakthrough Therapies for Rare Inflammatory Diseases

Anabasum is a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Learn more Career Opportunities
About

About

Corbus Pharmaceuticals is a Phase 3 clinical stage pharmaceutical company focusing on rare, life-threatening, chronic inflammatory diseases.

Learn More
Technology

Technology

Our technology revolves around the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases.

Learn More
Indications

Indications

Corbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with rare chronic inflammatory conditions.

Learn More

Pipeline

Corbus Pharmaceuticals is developing anabasum for the treatment of rare, chronic and serious inflammatory and fibrotic diseases.

View Details
Preclinical Phase 1 Phase 2 Phase 2b Phase 3
Systemic Sclerosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 2b Phase in progress
Phase 3 Phase not started
Cystic Fibrosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started
Dermatomyositis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started
Systemic Lupus Erythematosus
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started

Sign up for Email Alerts

Receive breaking news first!

Sign up today